Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30825174 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL20738520 | 0.86 | NOTUM (0.44) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL31373870 | 0.86 | NOTUM (0.44) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL28029965 | 0.85 | MEN1 (0.45) | MEN1KMT2AALDH1A1POLBCYP1A2 | |
| SCHEMBL24926039 | 0.81 | CES1 (0.46) | MEN1KMT2AALDH1A1HPGDGPR3 | |
| SCHEMBL28247397 | 0.80 | RAB9A (0.38) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL29338286 | 0.80 | MEN1 (0.37) | MEN1KMT2AALDH1A1HPGDGPR3 | |
| SCHEMBL28246631 | 0.80 | EDNRB (0.44) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL28559637 | 0.79 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1POLBHPGD | |
| SCHEMBL28159474 | 0.79 | EDNRB (0.43) | MEN1KMT2AALDH1A1POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080120-B1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-06-19 | — | — | EP | disclosed |
| CN-108601766-A | Cxcr2 inhibitor | 凯莫森特里克斯股份有限公司 | 2018-09-28 | — | — | CN | disclosed |
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BY) | 2018-06-26 | — | — | US | disclosed |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| EP-3080120-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086512-A1 | FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004737-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | TNF, TNFRSF1A, TNFRSF9 | MEN1 3445/4885KMT2A 4392/4885ALDH1A1 1594/4885 |
| US-20170128445-A1 | Fused Imidazole and Pyrazole Derivatives as Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | MEN1 3409/4885KMT2A 4392/4885ALDH1A1 1651/4885 |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | MEN1 3212/4885KMT2A 1495/4885ALDH1A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.